Similar articles for PMID: 11217868

Year	Number of Results
1996	1
1997	1
1998	9
1999	10
2000	10
2001	29
2002	20
2003	20
2004	22
2005	14
2006	6
2007	6
2008	8
2009	6
2010	5
2011	9
2012	6
2013	9
2014	7
2015	6
2016	3
2018	1
2019	9
2020	6
2021	5
2022	2
2023	2
2024	1

1

The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.

Moyle G. Moyle G. Drugs. 2001;61(1):19-26. doi: 10.2165/00003495-200161010-00003. Drugs. 2001. PMID: 11217868 Review.

2

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V. Delaugerre C, et al. J Med Virol. 2001 Nov;65(3):445-8. J Med Virol. 2001. PMID: 11596076

3

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG. Matthews GV, et al. AIDS. 2002 Jan 4;16(1):53-61. doi: 10.1097/00002030-200201040-00008. AIDS. 2002. PMID: 11741163 Clinical Trial.

4

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.

Casado JL, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, Arnó A, Garcia-Arata I, Bloor S, Bonjoch A, Blazquez J, Clotet B, Larder B. Casado JL, et al. AIDS. 2000 Jan 28;14(2):F1-7. doi: 10.1097/00002030-200001280-00001. AIDS. 2000. PMID: 10708276

5

NNRTIs: a neglected class.

Cadman J. Cadman J. GMHC Treat Issues. 1998 Sep;12(9):6-10. GMHC Treat Issues. 1998. PMID: 11365807

6

Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.

Torre D, Tambini R, Speranza F. Torre D, et al. HIV Clin Trials. 2001 Mar-Apr;2(2):113-21. doi: 10.1310/4KVA-U5H3-UBXT-84G7. HIV Clin Trials. 2001. PMID: 11590519

7

Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection.

Moyle GJ. Moyle GJ. Curr Opin Infect Dis. 2000 Feb;13(1):19-25. doi: 10.1097/00001432-200002000-00004. Curr Opin Infect Dis. 2000. PMID: 11964768

8

Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.

Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, Casado JL, Dronda F, Gutiérrez C, Quereda C, Navas E, Abraira V, Rodríguez MA. Pérez-Elías MJ, et al. HIV Clin Trials. 2005 Nov-Dec;6(6):312-9. doi: 10.1310/B3NK-V5XQ-6VX9-5DEK. HIV Clin Trials. 2005. PMID: 16452065 Clinical Trial.

9

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

De Clercq E. De Clercq E. Antiviral Res. 1998 Jun;38(3):153-79. doi: 10.1016/s0166-3542(98)00025-4. Antiviral Res. 1998. PMID: 9754886 Review.

10

Clinical utility of current NNRTIs and perspectives of new agents in this class under development.

Zhang Z, Hamatake R, Hong Z. Zhang Z, et al. Antivir Chem Chemother. 2004 May;15(3):121-34. doi: 10.1177/095632020401500302. Antivir Chem Chemother. 2004. PMID: 15266894 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

225 results

Results by year